Full video transcriptClick to expand
Auto-generated transcript of @paulbakhtiar's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00The number one peptide when it comes to sexual health
- 0:02would be PT-141.
- 0:03PT-141 is FDA approved for women.
- 0:07It helps to increase their sexual frequency,
- 0:09their sexual desire,
- 0:11in addition to their orgasm score goes up.
- 0:13And it is also healthy for men to use it as well.
- 0:16It bypasses the cardiovascular system
- 0:18and it goes directly to the MC4 receptor.
- 0:20And that's how it's actually increasing the libido,
- 0:23also the erection size.
- 0:25So it's a much safer option typically
- 0:28than we'll say some of the blue pills that are out there.
PT-141 for sexual health: what the FDA approval actually means
Quick answer
Bremelanotide (Vyleesi) is FDA-approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder and carries a prescribing warning about transient blood pressure elevation after each dose, making the 'bypasses the cardiovascular system' framing in this video clinically inaccurate. Off-label use in men has some early-phase data but no FDA approval, and claims about erection size specifically are not supported by controlled trial outcomes. Compounded PT-141 peptide products are not equivalent to FDA-approved bremelanotide and lack the same regulatory oversight on purity and dosing.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
PT-141 (Bremelanotide) access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For PT-141 for sexual health: what the FDA approval actually means, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
VYLEESI (bremelanotide injection) FDA Prescribing Information
Bremelanotide (PT-141) is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women; approval is limited to that indication.
FDA
Bremelanotide for Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Pivotal RECONNECT studies: two double-blind placebo-controlled Phase 3 trials (1,267 women) showing improved sexual desire and reduced distress versus placebo.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
PT-141 (Bremelanotide) is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "PT-141 for sexual health: what the FDA approval actually means" from Paul Bakhtiar. We read the clip as a Peptide social video fact-checks claim about PT-141 (Bremelanotide), then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Bremelanotide (Vyleesi) is FDA-approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder and carries a prescribing warning about transient blood pressure elevation after each dose, making the 'bypasses the cardiovascular system' framing in this video clinically inaccurate.
The reason this review is not generic is the source wording and the canonical claim label "peptides peptides for se ual health se ual health support isn t one s." In this clip, the useful excerpt is: "The number one peptide when it comes to sexual health would be PT-141." That wording changes the review because it points to PT-141 (Bremelanotide) safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against VYLEESI (bremelanotide injection) FDA Prescribing Information (2019), Bremelanotide for Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (2019), and Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide (2022), plus the creator's own wording. PT-141 (Bremelanotide) still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Bremelanotide (Vyleesi) is FDA-approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder and carries a prescribing warning about transient blood pressure elevation after each dose, making the 'bypasses the cardiovascular system' framing in this video clinically inaccurate.
FormBlends verdict
PT-141 (Bremelanotide) safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the PT-141 (Bremelanotide) guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Bremelanotide (Vyleesi) is FDA-approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder and carries a prescribing warning about transient blood pressure elevation after each dose, making the 'bypasses the cardiovascular system' framing in this video clinically inaccurate. Off-label use in men has some early-phase data but no FDA approval, and claims about erection size specifically are not supported by controlled trial outcomes. Compounded PT-141 peptide products are not equivalent to FDA-approved bremelanotide and lack the same regulatory oversight on purity and dosing.
- Bremelanotide (Vyleesi) received FDA approval in June 2019, but only for premenopausal women with acquired, generalized HSDD, not all women and not men.
- The FDA label for Vyleesi includes a warning about transient blood pressure increases after each dose, directly contradicting the 'bypasses the cardiovascular system' claim.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- PT-141 (Bremelanotide) decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the PT-141 (Bremelanotide) guide, cost path, safety notes, and provider review before acting.
Review PT-141 (Bremelanotide)What You'll Learn
- Bremelanotide (Vyleesi) received FDA approval in June 2019, but only for premenopausal women with acquired, generalized HSDD, not all women and not men.
- The FDA label for Vyleesi includes a warning about transient blood pressure increases after each dose, directly contradicting the 'bypasses the cardiovascular system' claim.
- In Clayton et al. (2016, Journal of Sexual Medicine), the primary trial endpoints were desire improvement and distress reduction, not orgasm scores, which appeared only as secondary measures.
- No FDA-approved indication exists for bremelanotide in men, and 'erection size' as a specific outcome has no controlled trial support in peer-reviewed literature.
- Nausea occurred in approximately 40 percent of patients in Vyleesi clinical trials, a side effect profile the video does not mention.
- Compounded PT-141 peptide products sold through wellness clinics are not the same as FDA-approved Vyleesi and are not subject to the same purity, potency, or sterility standards.
- PDE5 inhibitors and bremelanotide work through completely different mechanisms and cannot be compared for safety without individual patient cardiovascular risk assessment.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @paulbakhtiar actually say?
The creator made five distinct claims about PT-141 (bremelanotide): it is the top peptide for sexual health, it is FDA-approved for women, it increases sexual frequency, desire, and orgasm scores, it is safe for men, and it "bypasses the cardiovascular system" by acting on the MC4 receptor, making it safer than PDE5 inhibitors like sildenafil. That last claim is where things get complicated, and it deserves real scrutiny.
To be clear about framing: this is a short-form TikTok clip, not a clinical consultation. But 40,000 people watched it, and incomplete framing around a drug with known cardiovascular effects is not a small problem.
Does the science back this up?
Partially, yes. Bremelanotide (Vyleesi) received FDA approval in June 2019 specifically for premenopausal women with hypoactive sexual desire disorder (HSDD). The pivotal trials, specifically Clayton et al. (2016, Journal of Sexual Medicine), showed statistically significant improvements in desire and reductions in distress, though effect sizes were modest. The orgasm score improvement the creator references does appear in some study endpoints, though it was not the primary outcome.
The MC4 receptor mechanism is real. Unlike sildenafil, which works peripherally on vascular smooth muscle, bremelanotide acts centrally via melanocortin receptors in the hypothalamus. That distinction is scientifically legitimate. However, the phrase "bypasses the cardiovascular system" is where this claim breaks down badly. The FDA label for Vyleesi includes an explicit warning about transient increases in blood pressure following each dose, sometimes up to 6 mmHg systolic. That is a cardiovascular effect, full stop.
What did they get wrong (or right)?
They got the FDA approval status right. They got the mechanism right in broad strokes. They got the libido and desire data roughly right for women with HSDD.
What they got wrong matters more. Saying bremelanotide "bypasses the cardiovascular system" is inaccurate and potentially dangerous framing. The drug has a black-box-adjacent warning: it is contraindicated in patients with cardiovascular disease, and the label explicitly states blood pressure should not be monitored with a cuff during the 12-hour post-dose window because it can give false readings. The FDA approved it with a Risk Evaluation and Mitigation Strategy (REMS) program specifically because of these concerns.
The claim about "erection size" also lacks clinical support. The evidence for bremelanotide in men is limited and not FDA-approved for that indication. Simon et al. (2019, Journal of Sexual Medicine) showed some signal for erectile function in men, but "erection size" as a specific outcome is not established in the peer-reviewed literature. Saying it increases erection size is an overreach.
- Cardiovascular safety claim: inaccurate. The drug causes transient hypertension.
- FDA approval for women with HSDD: accurate.
- Central MC4 receptor mechanism: accurate.
- "Erection size" improvement in men: not supported by current evidence.
- Safer than PDE5 inhibitors categorically: misleading without context.
What should you actually know?
Bremelanotide is a real, FDA-approved drug with a specific indication: premenopausal women with acquired, generalized HSDD. That is a narrower population than "women" broadly. It is not approved for men in any jurisdiction as of this writing, and off-label use in men exists but has limited controlled trial data. Anyone considering it should know: nausea is the most commonly reported side effect, occurring in roughly 40 percent of patients in trials. The blood pressure effect is real and clinically meaningful for anyone with hypertension or cardiovascular risk factors.
Comparing it to "blue pills" as categorically safer ignores that PDE5 inhibitors have decades of safety data across millions of patients. Bremelanotide was approved in 2019 and has a much shorter post-market safety record. Neither drug is universally safer. They work differently, and the comparison requires a real clinical conversation, not a TikTok.
Compounded versions of PT-141 circulating in the peptide market are not the same as FDA-approved Vyleesi. Purity, dosing accuracy, and sterility are not guaranteed outside regulated pharmacy channels.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Paul Bakhtiar · TikTok creator
40.8K views on this video
Peptides for Se❌ual Health | Se❌ual health support isn’t one-size-fits-all—some peptides may help address it at the root. Some things to consider: ✔️ FDA-approved for women – may support sexual frequency, desire, and overall satisfaction. ✔️ Safe for men too – may help with libido and erection quality. ✔️ Unique mechanism – may bypass the cardiovascular system by acting on the MC4 receptor, offering an alternative to traditional PDE5 inhibitors. 💡 PT-141 may be a valuable option for se❌ual heal
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about bremelanotide (vyleesi) received fda approval in june 2019,?
Bremelanotide (Vyleesi) received FDA approval in June 2019, but only for premenopausal women with acquired, generalized HSDD, not all women and not men.
What does the video say about the fda label for vyleesi includes a warning about transient?
The FDA label for Vyleesi includes a warning about transient blood pressure increases after each dose, directly contradicting the 'bypasses the cardiovascular system' claim.
What does the video say about in clayton et al. (2016, journal of sexual medicine), the?
In Clayton et al. (2016, Journal of Sexual Medicine), the primary trial endpoints were desire improvement and distress reduction, not orgasm scores, which appeared only as secondary measures.
What does the video say about no fda-approved indication exists for bremelanotide in men,?
No FDA-approved indication exists for bremelanotide in men, and 'erection size' as a specific outcome has no controlled trial support in peer-reviewed literature.
What does the video say about nausea occurred in approximately 40 percent of patients in vyleesi?
Nausea occurred in approximately 40 percent of patients in Vyleesi clinical trials, a side effect profile the video does not mention.
What does the video say about compounded pt-141 peptide products sold through wellness clinics?
Compounded PT-141 peptide products sold through wellness clinics are not the same as FDA-approved Vyleesi and are not subject to the same purity, potency, or sterility standards.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Paul Bakhtiar, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.